Adrian Reuben 2020

1

CURRICULUM VITAE Adrian Reuben, MBBS, FRCP, FACG, FAASLD Date of Birth: March 4th, 1945 Citizenship: United States and United Kingdom Marital Status: Widowed 2015 Children: Sara Elizabeth (1984) and Aaron Samuel (1985) Correspondence: see Residence below Email: Preferred - adrianreuben789@gmail.com; Secondary - reubena@musc.edu Tele: UK Mobile (Cell) 44 (0)7885 666060 UK Landline 44 (0)208 346 8475 Residence: Flat 2 Clementine Court, 4 Dollis Park, Finchley Church End London N3 1HG, United Kingdom EDUCATION:

1963-1966 University College London, Preclinical studies including B. Sc. (1st Class) Pharmacology

1966-1969 University College Hospital, London, Medical Degree (M.B.B.S.) 1972 Member of the Royal College of Physicians (M.R.C.P.)

SCHOLARSHIPS, AWARDS AND HONORS: 1963-1965 Physiology Prize 1966-1969 Fellows Gold Medal in Medicine at UCH (London) 1969 Honors in Pathology and Applied Pharmacology at MBBS Examination 1979-1980 MRC Traveling Scholarship (Eli Lilly Fellowship) 1980-1981 American Liver Foundation Postdoctoral Fellowship 1983-1987 NIH: Clinical Investigator Award 1987-1989 American Heart Association: Connecticut Chapter/Affiliate Grant-in-Aid 1989-1996 NIH: Independent Research Grant (RO1) 1990 Elected Fellow of the Royal College of Physicians, London (FRCP) 1995-2008 Best Doctors in America: Southeast Region 1999-2012 Best Doctors in America 2000-2012 Who’s Who in Medicine and Healthcare 2005 Elected Fellow of the American College of Gastroenterology (FACG) 2006 Outstanding Clinician of the Year, Medical University of South Carolina Elected Fellow of the American Association for the Study of Liver Diseases (FAASLD) 2008-2009 Who’s Who Among Executives and Professionals “Honors Edition”

Adrian Reuben 2020

2

2019 Marquis Who’s Who Lifetime Achievement Award 2019 AASLD Distinguished Service Award 2020 Elected American Gastroenterology Association Fellow (AGAF) 2020 Honorary Visiting Professor, Institute of Hepatology, King’s College London, UK MEMBERSHIP/SOCIETIES (Strike through indicates inactive) British Society of Gastroenterology (BSGE) Royal College of Physicians, London (RCP) Goon Show Preservation Society (GSPS) American Association for the Study of Liver Diseases (AASLD) American Gastroenterology Association (AGA) International Association for the Study of Liver Disease (IASL) European Association for the Study of Liver Disease (EASL) American College of Gastroenterology (ACG) Israeli Association for the Study of the Liver (IsASL) APPOINTMENTS Employer Position From To Medical University of South Carolina Professor Emeritus 01/2015 06/2018 Division Gastroenterology & Hepatology Part time faculty Charleston, South Carolina Medical University of South Carolina Professor Emeritus 01/2015 present Division Gastroenterology & Hepatology Charleston, South Carolina Medical University of South Carolina Professor of Medicine 12/1993 12/2014 Division Gastroenterology & Hepatology Charleston, South Carolina Digestive Diseases Division Associate Professor 07/1986 11/1993 Yale University School of Medicine of Medicine Liver Study Unit Assistant Professor 10/1981 06/1986 Yale University School of Medicine of Medicine Central Middlesex Hospital Senior Registrar 10/1978 09/1979 London, England Guys Hospital Medical School Research Fellow and 10/1976 09/1978 London, England Hon. Senior Registrar Middlesex Hospital Research Fellow and 02/1976 09/1976 London, England Hon. Registrar

Adrian Reuben 2020

3

Soroka Medical Center Resident Physician 05/1975 01/1976 Be’er Sheva, Israel Renal Unit Middlesex Hospital Registrar 11/1972 02/1975 London, England National Heart Hospital Senior House Officer 01/1972 08/1972 London, England Brompton Hospital Senior House Officer 07/1971 12/1971 London, England Hammersmith Hospital Senior House Officer 01/1971 06/1971 London, England St. Pancras Hospital House Surgeon 06/1970 11/1970 London, England University College Hospital House Physician 11/1969 05/1970 London, England Faculty of Medicine, Visiting Professor 10/2011 05/2012 Hebrew University of Jerusalem and Hadassah Medical Center, Ein Kerem, Israel Faculty of Medicine, Visiting Professor 01/2018 01/2019 Hebrew University of Jerusalem, Israel Institute of Hepatology, Visiting Professor 01/21/2020 King’s College London, UK ADMINISTRATION Chief of Liver Service 02/1993 12/2014 Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina COMMITTEES (*indicates current)

(a) International, National and Local *Goon Show Preservation Society, United Kingdom

Adrian Reuben 2020

4

Abstract Committee, Biliary Tract Diseases Section, American Gastroenterology Association, 1991. Research Committee, American Association for the Study of Liver Diseases, 1989-1992. Veterans’ Administration Merit Review Board in Digestive Diseases, 1992-1995. Chairman, Veterans’ Administration Merit Review Board in Digestive Diseases, 1994-1995. Editorial Board, “The Gastroenterologist” 1993-1995. Publication Committee, American Association for the Study of Liver Diseases, 1993-1996. Ad Hoc Member, Study Section, Digestive Diseases Research Core Grants NIH 1994 Abstract Committee, Clinical Practice, American Gastroenterology Association 1995. Abstract Committee, Association for the Study of Liver Diseases (AASLD) Annual Meeting, 2000. Data Safety Monitoring Board, Roche Study MYCS 2646 AST Practice Guidelines Committee 1998-2000 AST Abdominal Organ Committee 1998-2000 Ad Hoc Member, Study Section: Clinical Research Network in Non-Alcoholic Steatohepatitis (2001) Ad Hoc Member, NIH Study Section: Living Donors for Liver Transplantation (2002) Ad Hoc Member, NIH Study Section: Hepatitis B Clinical Research Network (2008) AASLD Abstract Review Committee AASLD Publications Committee OPTN/UNOS Liver and Intestinal Organ Transplantation Committee (2002-2004) Editorial Board Liver Transplantation 2004-2009 Chair, Data Safety Monitoring Board, Idenix/Novartis Telbivudine (LdT) Clinical Phase III Studies Data Safety Monitoring Board, Nucleonics RNAi and DNA-based of viral hepatitis Chair, Data Safety Monitoring Board, Hyperion Phase II Randomized Trial of Ammonul for Stage 3 or 4 Hepatic Encephalopathy Editorial Board, World Journal of Gastroenterology 2004-2009 AASLD Nominating Committee 2006-2007 AST Abstract Review Committee *AASLD Special Interest Group – Portal Hypertension *AASLD Special Interest Group – Hepatotoxicity Steering Committee (Vice-Chair 2018-2019, and Chair 2020-2021) *AASLD Continuing Medical Education Committee *Acute Liver Failure Study Group Chair, Ethics Committee, American Association for the Study of Liver Disease 2011-2012 Data Safety Monitoring Board, Presidio Pharmaceuticals Inc. Phase I Study in Hepatitis C Data Safety Monitoring Board, Novira Therapeutics Inc Inc. Phase III Study in Hepatitis B Charleston Medical Society Ad Hoc Town/Gown Committee Advisory Board Arnold/Yaschik Jewish Studies Program, College of Charleston, and Chair, Adult Book Club Board of Trustees of Synagogue Emanu-el, Charleston SC. *Member Causality Adjudication Committee, Acute Liver Failure Study Group

Adrian Reuben 2020

5

(b) Medical University of South Carolina

Medical Records Advisory Committee Marketing Task Force Research Development Subgroup, Strategic Planning Committee Transplant Marketing Task Force Communications Committee, Digestive Disease Center (DDC) Liaison, Pharmacy and Therapeutics Committee Patient Satisfaction Committee Quality Improvement Council University Tenure Committee OACIS Expansion Steering Committee University Faculty Senate 1997-2001 Chair, Faculty Senate 1998-2001 President’s Council 2000-2001 RFP Evaluation Committee Clinical Information Management Council Activated Protein C Guidelines Committee Transplant Information System Oversight Committee, Chair OACIS Implementation Group ROTEM Implementation Group Prior TEACHING (MUSC) Yale 2nd Year Pathophysiology Course MUSC Annual GI Topics Conference Physiology, 1st Year Medical Students Physical Diagnosis, 2nd Year Medical Students Clinical Correlations, 3rd Year Medical Students Bedside Clinical Diagnosis, 3rd Year Medical Students, Hebrew University School of Medicine and Shaare Zedek Medical Center, Jerusalem, Israel INVITED LECTURES AND SYMPOSIA 1979-1989 Dept. of Medicine, Ben-Gurion University Medical School, Beer Sheba, Israel (1979) Gastroenterology Dept., Technion Medical School, Haifa Israel (1979) Falk Symposium #29, Bile Acids and Lipids, Freiberg W. Germany (1980) Gastroenterology Section, Northwestern University Medical School, Chicago IL (1981) Section of Gastroenterology, Boston University Hospital, Boston MA (1981) Falk Symposium #33, Bile Acids and Cholesterol in Health and Disease, Basel Switzerland (1982) Kroc Foundation Conference, the Physical Chemistry of Bile in Health and Disease (1983) Dept. of Surgery, Hospital of St. Raphael, New Haven CT (1985)

Adrian Reuben 2020

6

Division of Gastroenterology, State University of New York at Buffalo (1986) Dept. of Medicine, Bridgeport Hospital, Bridgeport CT (1987) Gastroenterology Dept., Duke University School of Medicine, Durham NC (1988) Section of Gastroenterology, Boston University Hospital, Boston MA (1988) GI Division, University of California San Diego School of Medicine, San Diego CA (1988) Division of Gastroenterology/Hepatology, University of Iowa School of Medicine, Iowa City IA (1988) Division of Gastroenterology, Baylor College of Medicine, Houston TX (1988) Division of Gastroenterology, University of Michigan, Ann Arbor MI (1988) Gastroenterology Section, Medical College of Virginia, Richmond VA (1988) Grand Rounds, Dept. of Medicine, Yale University School of Medicine, New Haven CT (1989) NIH-Sponsored workshop on Frontiers in Gallstone Formation, Virginia 1989 Preventative Cardiology Seminar Series, Yale University School of Medicine, New Haven CT (1989) Grand Rounds, Dept. of Anesthesiology, Yale University School of Medicine (1989) 1990-2000 Grand Rounds Dept. of Medicine, Yale University School of Medicine, New Haven CT (1990) Update on Hepatitis C, Connecticut Chapter, American College of Physicians (1990) GI Division, Brown University, Rhode Island (1991) Grand Rounds, Dept. of Obstetrics and Gynecology, Yale University School of Medicine (1992) GI Division, Medical University of South Carolina, Charleston SC (1992) South Carolina Chapter of the American College of Surgeons (1996) Visiting Professor, University of Vermont College of Medicine (1996) MUSC Family Medicine Symposium (1997, 1998, 1999, 2000) AASLD/ILTS Postgraduate Course in Liver Transplantation, Chicago IL (1997) Presbyterian’s Thirteenth Annual Cancer Center Symposium, Charleston SC (2000) Texas Club of Internists Annual Internal Medicine Update, Charleston SC (2000) 2001-2010 Digestive Disease Week (DDW) Postgraduate Course (2001) AASLD/ILTS Postgraduate Course in Liver Transplantation, Dallas (2001) Medical Grand Rounds, Medical University of South Carolina (2001, 2002, 2003, 2004) Medical Grand Rounds, Crozier Chester Medical Center, “Leave Off Gormandizing: A National Epidemic and the Liver (2003) University of Florida at Tampa Liver Club “Risks of Surgery in Patients with Liver Disease (2004) University of Texas Southwestern Medical Center at Dallas, What’s new in Gastroenterology and Hepatology, “The Epidemic of NAFLD” (2004) Greenville Memorial Hospital Grand Rounds, Greenville SC: Non-alcoholic Fatty Liver Disease (2004) Grand Rounds, Spartanburg Regional Medical Center, Spartanburg SC: Non-Alcoholic Fatty Liver Disease (2004) Southern Medical Association, CME Conference 2004: Medical Dilemmas in Primary Care -Laboratory Investigation of Liver Disease -Hepatitis C

Adrian Reuben 2020

7

-Nonalcoholic Fatty Liver Disease: Another Facet of the Metabolic Syndrome Medical College of Georgia, Augusta GA: Medical and Surgical Approaches to GI Disorders 2004 -Evaluation of the Liver Transplant Candidate AASLD Annual Meeting 2004 – Moderator Scientific Session MUSC Primary Care Conference 2004: Update on Viral Hepatitis Grand Rounds, Dept. of Surgery, Medical University of SC (2005) University of Alabama, Birmingham – Hepatology Update; After-dinner keynote address (2005) Yale Division of Gastroenterology and Hepatology; 50th Founding Celebration – After-dinner address (2006) University of Florida at Tampa, Gastroenterology Update: “Drug hepatotoxicity” and “Hepatocellular Carcinoma” (2006) Acute Liver Failure Study Group, “Acute Liver Failure Due to Drug-induced Liver Injury” (2006) Medicine Grand Rounds, University of South Carolina Department of Medicine, Columbia SC: Complications of cirrhosis (2006) Johns Hopkins University Annual Gastroenterology Update: “Risk of surgery in patients with cirrhosis” and “History of Hepatology” (2006) Medicine Grand Rounds, University of Memphis Tennessee: “Autoimmune Hepatitis” and Lecture to Division of Gastroenterology & Hepatology, “Risks of surgery in patients with liver disease” (2006) Emory University Transplant Program: Long-term management of the liver transplant recipient (2006) American College of Gastroenterology Annual Meeting 2006: Lunchtime Learning Session “Drug Hepatotoxicity” American Association for the Study of Liver Disease, Early Moring Workshop: “Causality in Drug-Induced Liver Disease” (2006) NIH Focus Conference on Acute Liver: “Acute Liver Failure due to Drug-Induced Liver Disease” (2006) Acute Liver Failure Study Group, “Epidemiology, Causes and Outcomes of Acute Liver Failure at the Medical University of South Carolina” (2006) Hepatic historiography, Yale University Digestive Diseases (2006) Grand Rounds, Dept. of Medicine B, Soroka Medical Center, Be’er Sheva, Israel (2007) GI Grand Rounds, Ichelov Medical Center, Tel Aviv Israel (2007) Hepatology Grand Rounds, Rambam Medical Center, Haifa Israel (2007) Keynote speaker, Roberto J. Groszmann Symposium on Portal Hypertension (2007 State of the Art Lecture, American College Rheumatology Annual Meeting (2007): “Extrahepatic Manifestations of Hepatitis C.” AASLD Annual Meeting Interferon Symposium, Keynote Speaker on History of Discovery of Interferons (2007) Chair, Clinical Research Session, American Transplant Congress, Toronto Canada (2008) Update on Viral Hepatitis, MUSC Annual Family Medicine Course, Kiawah Island, SC (2008) AASLD Annual Meeting 2008: Presenter of Distinguished Service Award to Dr. Andres T. Blei. UCLA Update in Gastroenterology and Hepatology: Risk of Surgery in patients with Liver Disease Lecture, Laguna Niguel CA (2008)

Adrian Reuben 2020

8

Dept. of Surgery, Medical University of SC Grand Rounds: Estimating the risk of surgery in patients with liver disease (2009) Annual Endovascular Meeting (2009), Kiawah Island SC: Epidemiology and Pathogenesis of Hepatocellular Carcinoma Argentine Association for the Study of Liver Disease, Buenos Aires Argentina (2009)

-History of Liver Disease – Facts and Fancies -Treatment of Non-Alcoholic Fatty Liver Disease -Risk of Surgery in Patients with Liver Disease -Use of Ursodeoxycholic Acid in Liver Disease

Grand Rounds, Dept. of Medicine, University of Indiana Medical Center: Cirrhosis is an extrahepatic disorder (2009) Division of Gastroenterology & Hepatology Grand Rounds, University of Indiana Medical Center: Estimating the Risk of Surgery in Patients with Liver Disease (2009) Findling Named Visiting Professor, Mayo Clinic Medical School, Rochester MN: Inaugural Lecture “Humanism in Medicine” (2009) Grand Rounds, Department of Medicine MUSC, Humanism in Medicine (2009) University Hospital, Augusta GA, Update on Non-Alcoholic Fatty Liver Disease (2009) AASLD Postgraduate Course in Liver Disease (2009), Evaluation of the Transplant Recipient Exalenz Meeting, Boston (2009), Methacin Breath Test in Liver Disease Recife Portal Hypertension and Hepatocellular Carcinoma Course, Recife Brazil (2009)- Lectures on: (i) Variceal bleeding

(ii) History of portal hypertension (iii) Pathophysiology of ascites, hepatopulmonary syndrome, and hepatorenal syndrome (iv) Epidemiology and pathogenesis of hepatocellular carcinoma (v) Staging and diagnosis of hepatocellular carcinoma

Southern Medical Association Annual meeting (2009), New York NY; Lectures on variceal bleeding, ascites, liver transplantation, and case presentations Medical College of Georgia, Update in Gastroenterology (2010) “Evaluation of the Liver Transplant Recipient, Kiawah Island, SC Medical Grand Rounds, MUSC, Cirrhosis is an Extrahepatic Disorder (2010) Annual DDW Meeting 2010, Co-Chair Practitioner’s Corner “What’s New and Hot in Clinical Hepatology” Annual DDW Meeting 2010, The Liver Patient in the ICU Clinical Symposium Binghamton NY, 33rd Annual Gastroenterology Update (2010)

-Update on Viral Hepatitis -The Liver and Pregnancy 2011 – 2018

University of Berne, Switzerland Grand Rounds Gastroenterology and Hepatology, March 2011 Hadassah University Medical Center, Institute of Gastroenterology (2012); Four lectures series in Hepatology, Israel Grand Rounds, Division of Gastroenterology, Ichilov Hospital, Tel Aviv University, Tel Aviv Israel March (2012) IsASL Annual Liver Conference Invited Lecture, March 2012 Shaare Zedek Hospital, Jerusalem: Three lecture series in Hepatology April 2012

Adrian Reuben 2020

9

AASLD Postgraduate Course, November 2012. Ethics of genetic testing. UT Southwestern: Burton Combes Endowed Lecture, February 2013; Hepatic historiography Grand Rounds Department of Surgery MUSC March 2013. Risk of Surgery in the Patient with Liver Disease 42ndAnnual Postgraduate Course in Surgery, Charleston SC April 2013. My patient Has Cirrhosis – Should I Operate? Grand Rounds Division of Gastroenterology and Hepatology, University of Arkansas. August 2013. Myths of the INR: Liver Disease Does Not Predispose to Procedure-Related Bleeding Grand Rounds Department of Anesthesiology, MUSC September 2013. Myths of the INR: Liver Disease Does Not Predispose to Procedure-Related Bleeding American College of Gastroenterology Postgraduate Course October 2013 – Drug-Induced Cholestasis AASLD Postgraduate Course, Concluding Perspectives – Future Horizons in Treatment of Liver Disease. Washington DC, November 2013. AASLD Annual Meeting 2013, Washington DC. Moderator: Early Morning Workshop. Ethical Considerations in the Treatment of patients with Substance-dependency. November 2013 Mercy Medical Center 6th Annual Consensus and Controversies in Gastroenterology & Hepatology, Baltimore MD, September 2014

- Managing Hospitalized Patients with Liver Disease - Myths of the INR: Liver disease does not predispose to procedure-related bleeding

Grand Rounds Department of Medicine MUSC December 2014. A crab by any other name – An update on hepatocellular carcinoma Israeli Association for the Study of the Liver. June 2015. Eilat, Israel

- Acute Liver Failure - Risk of Surgery in patients with Liver Disease - Coagulopathy in Liver Disease

Grand Rounds Department of Medicine Hadassah Medical Center, Jerusalem, Israel. Introduction to Hepatology. June 2015 Grand Rounds Department of Medicine Shaare Zedek Medical Center, Jerusalem. Introduction to Hepatology. June 2015 Liver Unit, Sheba Medical Center, Tel Hashomer Hospital, Ramat Gan, Israel. Update on hepatocellular Carcinoma June 2015. Grand Rounds Critical Care Medicine MUSC August 2015. Acute Liver Failure 6th International Coagulopathy in Liver Disease Symposium, Charlottesville VA October 2015, “John F Anderson Memorial Lecture” – Thrombosis, Hemostasis and Liver Disease – A History Grand Rounds Department of Medicine, Drexel University, Philadelphia. October 2015. Debunking the Myths of the INR Shaare Zedek Medical Center, Jerusalem. Grand Rounds Department of Medicine. Xenobiotica Hepatotoxica, December 22nd 2015 Sourasky Medical Center Tel Aviv, Ichilov Hospital, Gastroenterology Department 2015 Sourasky Medical Center Tel Aviv, Ichilov Hospital, Grand Rounds. The Treatment of Esophagogastric varices with An Eye to their Pathogenesis. December 28th Department of Medicine. Debunking the Myths of the INR: The truth of the Coagulopathy of Liver Disease. December 29th 2015 Sourasky Medical Center Tel Aviv, Department of Gastroenterology, Ichilov Hospital. Xenobiotica Hepatotoxica: Update on Drug-Induced Liver injury. January 11th 2016

Adrian Reuben 2020

10

Sourasky Medical Center Tel Aviv, Ichilov Hospital, Department of Surgery. The risk of Surgery in Patients with Liver Disease. January 13th 2016 Shaare Zedek Medical Center, Jerusalem. Gastroenterology Department. The Treatment of Esophagogastric Varices with an Eye to their Pathogenesis. January 24th 2016. Ohio State University Liver Symposium. Keynote address. The Myths of the INR. February 19th 2016 Harvard Medical School. Norman Grace Visiting Professorship, May 2017: (i) Debunking the Myths of the INR (ii) Cirrhosis is a Systemic Disorder – Something for Everyone in the Department of Medicine VII international Symposium on Coagulopathy in Liver Disease. Moderator. Rome October 2017 Annual meeting of IsASL May 2018, Eilat Israel – Risk of surgery in patients with liver disease and Kidney impairment in patients with cirrhosis Grand Rounds “Risk of surgery in patients with liver disease”, at DHU UNITY, Hôpital Beaujon Clichy, France. AASLD Annual meeting November 2018 San Francisco – moderator at Hepatotoxicity SIG symposium and co-presenter of Meet-the-Professor luncheon devoted to the Risk of surgery in patients with liver disease. Annual Hot Topics from AASLD 2018 Hyderabad, India, December 2018 – Amarapurkar Oration “Risks of Surgery in Patients with Liver Disease”, and Review of November 2018 AASLD Presentations on ALF and ACLF Institute of Liver and Biliary Sciences, New Delhi, India. December 2018 - Risks of Surgery in Patients with Liver Disease, and Xenobiotica Hepatotoxica – An update on Drug-Induced Liver Injury” 2019 – Royal Free Hospital London UK: Institute of Liver and Digestive Health. March 2019. The Risks of Surgery in Patients with Liver Disease. Shaare Zedek Medical Center, Jerusalem, Israel May 2019. Acute-on-Chronic Liver Failure Annual meeting of IsASL June 2019, Eilat Israel – A History of Hepatology AASLD Hepatotoxicity Special Interest Group (SIG) Annual Meeting Symposium November 2019– Monitoring patients for drug-induced hepatotoxicity Institute of Hepatology, King’s College London, February 2010 - An update on drug-induced liver injury. Pending University of Kansas Medical Center, April/May 2012. Division of Gastroenterology Grand Rounds - Risk of Surgery in Patients with Liver Disease; Department of Internal Medicine Grand Rounds - An update on drug-induced liver injury. School of Medicine in Málaga, Spain. Hepatology Meeting. May 2020. Risk of Surgery in Patients with Liver disease PEER REVIEWS

Adrian Reuben 2020

11

Reviewer for: (1) Biochem Biophys Acta, (2) Gastroenterology, (3) Transfusion, (4) Liver Transplantation, (5) Digestive Disease and Science, (6) Hepatology, (7) Scandinavian Journal of Gastroenterology, (8) Journal of Clinical Investigation, (9) American Journal of Gastroenterology, (10) European Journal of Gastroenterology and Hepatology, (11) Liver International, (12) World Journal of Gastroenterology, (13) American Journal of Physiology, (14) New England Journal of Medicine, (15) Cancer, (16) Journal of Clinical Gastroenterology (17) Liver International EDITORIAL POSITIONS Associate Editor, Hepatology: Section Editor “Landmarks in Hepatology” 2002-2006 Section Editor, Clinical Liver Disease, “History of Hepatology” Series 2018- COURSES DIRECTED Annual MUSC Liver Disease and Transplantation Symposium, Columbia SC 1995, 1996, 1997, in Charleston SC 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2007, 2009, 2011 RESEARCH INTERESTS Clinical:

a) Drug-induced liver disease b) Acute Liver Failure c) Non-invasive investigation of liver disease by metabolic breath testing* d) Coagulopathy in liver disease e) Risk of Surgery in Liver Disease f) History of Medicine – Hepatology

*former Former Laboratory:

a) Biliary lipid secretion b) Hepatic fibrogenesis c) Hepatic regeneration

Former CLINICAL PRACTICE (a) Inpatient care 5-6 months per year, including daily ward rounds with residents, medical students and fellows, and procedures (endoscopy and liver biopsy) – including supervision of GI fellows (b) On-call schedule weekday evenings (Monday-Thursday) 6-weekly, weekends and holidays 6-weekly (c) Outpatient Care

(i) Liver Clinic weekly (ii) Transplant Clinic weekly (iii) Endoscopy sessions weekly

Adrian Reuben 2020

12

Patient Evaluation and Care Committees (iv) Liver Imaging and Tumor Board weekly (v) Liver Transplant Selection Committee weekly (vi) Liver Transplant Patient Coordinator review weekly

MENTORING: Name Position of Mentee during Mentoring Gregory Bonner1 – Gastroenterology (GI) Fellow at Yale University School of Medicine (Yale)

Ravinder Mittal2,3 – GI Fellow at Yale Mikio Zeniya – GI Research Fellow at Yale and Jikei University, Tokyo, Japan John Polio1,3 – GI Fellow at Yale (deceased)

Victor Navarro2,3 – GI Fellow at Yale

Marian Haber2,3 – Resident in Pathology at Yale (deceased)

Guiseppe Morelli2,3 – GI Fellow at Medical University School of South Carolina (MUSC)2

Ira Willner2,3 – Assistant Professor GI/Hepatology at MUSC Glenn Harvin1,3 – GI Fellow at MUSC Joshua Evans1,3 – GI Fellow at MUSC

William Marsteller1,3 – GI Fellow at MUSC

David Koch2,3 – GI Fellow at MUSC

Scott Stewart2,3 – Assistant Professor Internal Medicine at MUSC

Matthew Kappas2,3 – medical student at MUSC

Jacob Townsend1,3 - Cardiology Fellow at MUSC

Iya Znoyko – Postdoctoral Fellow at MUSC

Miriam Levy2,3 – Research GI Fellow at MUSC and Resident Sydney Australia

Ravi Madhotra2,3 – Advanced GI Fellow at MUSC and Registrar, Liverpool, United Kingdom

Naondo Sohara2,3 – Research GI Fellow at MUSC and GI Fellow Gunma University, Japan

Peter Draganov2,3 – GI Fellow at MUSC

Carlos Noronha Ferreira2 - Avenida Professor Serviço de Gastrenterologia e Hepatologia, Hospital de Santa Maria, Centro Hospitalar Lisboa, Portugal

Elad Resnick3– Resident at Shaare Zedek Medical Center, Jerusalem, Israel

Itai Ashkenazi – Medical Student at the Hebrew University School of Medicine, Jerusalem, Israel3

1Currently in private practice, 2Currently university faculty member, 3Co-author with AR of presented abstract or published manuscript PUBLICATIONS: (a) Articles in Peer-Reviewed Journals

Adrian Reuben 2020

13

1. Britton KE, Suwank R, Tutawiroon C, Premoydin M, Reuben A, Narashimha K, Myers M, Wood T, and Brown NJG: Computer assisted blood background subtraction (CABBS) hepatology with 131I and 132I Bromsulphthalein (BSP). Dynamic Studies with Radioisotopes in Medicine, 1974; 1: 157-172, International Atomic Energy Agency, Vienna.

2. Stamp TC, Haddad J, Exton-Smith AM, Reuben A, Twigg CA: Assay of vitamin D and its metabolites. Ann. Clin. Biochem. 1976;13:571-577.

3. Reuben A, Hirsch M, Berlyne GM: Renal vein thrombosis as the cause for the deterioration in renal function in familial Mediterranean fever. Quart. J. Med. 1977;46:243.

4. Shainkin-Kestenbaum R, Lerman R, Reuben A, Berlyne GM: Plasma calcitonin in chronic renal failure: relation to other factors of importance in bivalent ion metabolism. Clin. Sci. Mol. Med. 1977;52:577.

5. Reuben A, Johnson IJ, Cotton PB: Observer variation in pancreatogram interpretation. Br. J. Radiol. 1978;51:956-962.

6. Reuben A, Cotton PB: Operative pancreatic biopsy: A survey of current practice. Annals of the Royal College of Surgeons, England. 1978;60:53.

7. Reuben A, Cotton PB: ERCP in pancreatic cancer. Surg. Gynecol. Obst. 1979;148:179-184.

8. Maton PN, Reuben A, Dowling RH: Relationship between hepatic cholesterol synthesis and biliary cholesterol secretion in man; hepatic cholesterol synthesis is not a major regulator of biliary lipid secretion. Clin. Sc. 1982; 62:515-519.

9. Maton PN, Iser JH, Reuben A, Saxton HM, Murphy GM, Dowling RH: Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients with radiolucent gallstones. Medicine 61:86-87, 1982.

10. Reuben A, Howell KE, Boyer JL: Effects of taurocholate on the size of mixed lipid micelles and their association with pigment and proteins in rate bile. J. Lipid Res. 23:1039-1052, 1982.

11. Meier PJ, Sztul E, Reuben A, Boyer JL: Structural and functional polarity of canalicular and basolateral plasma membrane vesicles in high yield from rat liver. J. Cell Bio 98:991-1000, 1984.

12. Allgrove J, Adami S, Fraher L, Reuben A, O’Riordan JLH. Hypomagnesaemia: Studies of Parathyroid Hormone Secretion and Function. Clin. Endocrin. 21:435-449, 1984.

13. Reuben A, Maton PN, Murphy GM, Dowling RH. Bile lipid secretion in obese and non-obese individuals with and without gallstones. Clin. Sci. 69:71-79, 1985.

14. Reuben A, Allen RM. Intrahepatic sources of biliary-like micelles. Biochem. Biophys. Acta 876:1-12, 1986.

15. Reuben A, Quereshi Y, Murphy GM, Dowling RH. Effect of obesity and weight reduction on biliary cholesterol saturation and the response to chenodeoxycholic acid (CDCA). Eur. J. Clin. Invest. 16:133-142, 1986.

16. Mittal R, Reuben A, Whitney JO, McCallum RW. Do Bile Acid Reflux into the Esophagus in Normal Subjects or Gastroesophageal Reflux Patients? Gastroenterology 92:271-275, 1987.

17. Zeniya M, Reuben A. Triton WR1339-Induced Changes in Serum Lipids and Biliary Lipid Secretion. Am. J. Physiol. 254: G346-354, 1988.

18. Polio J, Groszmann RJ, Reuben A, Sterzel RB, Better OS: Portal Hypertension Ameliorates Arterial Hypertension in Spontaneously Hypertensive Rats. J Hepatology 8:294-301, 1989.

Adrian Reuben 2020

14

19. Genecin P, Polio J, Colombato LA, Ferraioli G, Reuben A, Groszmann RJ: Bile acids do not mediate the hyperdynamic circulation in portal hypertensive rats. Am. J. Physiol. 259:921-925, 1990.

20. Evans J, Reuben A, Craft J: PBC-95K, A 95 Kilodaiton Nuclear Autoantigen in Primary Biliary Cirrhosis. Arthritis and Rheumatism 34:731-736, 1991.

21. Sarin S, Groszmann RJ, Mosca P, Rojkind M, Stradecker MJ, Bhatnagar R, Reuben A, Dayal Y: Propranolol ameliorates the development of portal systemic shunting in a chronic murine schistosomiasis model portal hypertension. J. Clin. Invest. 87:1032-1036, 1991.

22. Petrides AS, Luzi L, Reuben A, Riely C, DeFronzo RA: Effect of insulin and plasma amino acid concentration on leucine metabolism in cirrhosis. Hepatology 14:432-441, 1991.

23. Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am. J. Gastroenterology 90:1250-1257, 1995.

24. Petersen KF, Rothman DL, Reuben A, West AB, Shulman GI. Noninvasive determination of hepatic triglyceride concentration in humans with 13C NMR spectroscopy. Hepatology 24:114-117, 1996.

25. Baliga P, Reuben A, Baker R, Baker S, Cofer J, Rajagopalan R. Intestinal transplantation: An early experience. Transplantation Proceedings 28:2734-2735, 1996.

26. Sindhi, R, Rosendale J, Mundy D, Taranto S, Baliga P, Reuben A, Rajagopalan PR, Hebra A, Tagge E, Othersen HB Jr. Impact of segmental grafts on pediatric liver transplantation – A review of the United Network for Organ Sharing Scientific Registry Data (1990-1996). J. Ped. Surgery 34:107-111, 1999.

27. Levy M, Trojanowska M, Reuben A. Oncostatin M: A cytokine upregulated in human cirrhosis increases collagen production by human hepatic stellate cells. J. Hepatol 32:218-226, 2000.

28. Morelli J, Mulcahy HE, Willner IR, Baliga P, Chavin KD, Patel R, Payne M, Cotton PB, Hawes RH, Reuben A, Cunningham JT. Endoscopic treatment of post-liver transplantation bile leaks with stent placement across the leak site. Gastrointest. Endosc. 54:471-475, 2001.

29. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96:2957-2961, 2001.

30. Madhotra R, Mulcahy HE, Willner IR, Reuben A. Prediction of esophageal varices in cirrhotic patients. J. Clin. Gastroenterol. 34:81-85, 2002.

31. Sohara N, Trojanowska M, Reuben A. Oncostatin M (OSM) stimulates tissue inhibitor of metalloproteinase-1 (TIMP-1) via a MEK-sensitive mechanism. J. Hepatology 36:191-199, 2002

32. Sohara N, Levy MT, Trojanowska M, Reuben A. Reversal of activation of human myofibroblast-like cells by culture on a basement membrane-like substrate. J. Hepatology 37:214-221, 2002.

33. Madhotra R, Mokhashi M, Willner IR, Hawes RM, Reuben A. Prospective evaluation of a 3.1mm battery-powered esophagoscope in screening for esophageal varices in cirrhotic patients. Am. J. Gastroenterology 98:807-812, 2003.

34. Verne GN, Soldevila-Pico C, Robinson ME, Spicer KM, Reuben A. Autonomic dysfunction and gastroparesis in cirrhosis. J. Clin Gastroenterology 2004; 38:72-76

35. Znoyko I, Sohara N, Spicer SS, Trojanowska M, Reuben A. Comparative studies of Oncostatin N expression in the tissues of adult rodents. Anatomical Record 283A:182-186, 2005.

Adrian Reuben 2020

15

36. Bowlus CL, Willner IR, Zern MA, Reuben A, Chen P, Holladay B, Xie L, Woolson RF, Strange C. Factors associated with advanced liver disease in adults with alpha-1 antitrypsin deficiency. Cl. Gastroenterol and Hepatol. 3:390-396, 2005.

37. Znoyko I, Sohara N, Spicer SS, Trojanowska M, Reuben A. Expression of Oncostatin M and its receptors in normal and cirrhotic human liver. J. Hepatol 43:893-900, 2005.

38. Znoyko I, Trojanowska M, Reuben A Collagen binding α2β1 and α1β1 integrins play contrasting roles in regulation of ETS-1 expression in human liver myofibroblasts. Molecular and Cellular Biochemistry 282:89-99, 2006.

39. Koch D, Christensen L, Lazarchick J, Stuart R, Reuben A. Post-transplant lymphoproliferative disorder – The great mimic in liver transplantation: Appraisal of the clinicopathologic spectrum and the role of EBV. Liver Transplantation 13:904-912, 2007.

40. Rutherford AE, Hynan LS, Borges CB, Forcione DG, Blackard JT, Lin W, Gorman AR, Shakikh OS, Reuben A, Harrison E, Reddy KR, Lee WM, Chung RT. Serum apoptosis markers in acute liver failure: a pilot study. Clin. Gastroenterol 5:1477-1483, 2007.

41. Poison J, Wians FH Jr, Orsulak P, Fuller D, Murray NG, Koff JM, Khan AL, Balko JA, Hynan LS, Lee WM and the Acute Liver Failure Study Group (includes Reuben A). Chim. Acta 39:24-30, 2008.

42. McGillicuddy JW, Lin A, Bratton C, Willner IR, Reuben A, Koch D, Baliga P, Chavin K. Laparoscopic hepatic resection: The MUSC experience. Journal of the SC Medical Association 104:241-275 2008.

43. Stewart SH, Reuben A, Brzezinski WA, Koch DG, Basile J, Randall PK, Miller PM. Preliminary evaluation of phosphatidylethanol and alcohol consumption in patients with liver disease and hypertension. Alcohol and Alcoholism 44:464-467, 2009.

44. Ishimaru D, Zuraw L, Ramalingam S, Sengupta TK, Bandyopadhyay S, Reuben A, Fernandes DJ, Spicer EK. Mechanism of regulation of bcl-2 mRNA by nucleolin and A+U-rich element-binding factor 1 (AUF1). J. Biol Chem, 285:27182-27191, 2010.

45. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: Results of a United States multicenter prospective study. Hepatology 52:2065-2076, 2010.

46. Koch DG, Bogatkevich G, Ramshesh V, Lemasters JJ, Uflacker R, Reuben A. Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans. Dig Dis Sci. 57:516-523, 2012.

47. Townsend J, Head R, Powers E, Reuben A. Usefulness of International Normalized Ratio to predict bleeding complications in patients with end-stage liver disease who undergo cardiac catheterization. Am. J. Cardiol. 2012;110:1062-1065.

48. Madan A, Barth KS, Balliet WE, Hernandez-Tejada MD, Borckardt JJ, Malcolm R, Willner I, Koch D, Reuben A. Chronic pain among liver transplant candidates. Prog. Transplant 2012; 22:379-384.

49. Stewart SH, Koch DG, Willner IR, Randall PK, Reuben A. Hair ethyl glucuronide is highly sensitive and specific for detecting moderate-to-heavy drinking in patients with liver disease. Alcohol Alcohol. 2013; 48: 83-87

50. Stewart S, Koch DG, Burgess DM, Willner IR, Reuben A. Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients. Alcoholism: Clinical and Experimental Research 2013; 37: 150-155

51. Stewart SH, Koch DG, Willner IR, Anton RF, Reuben A. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res 2014; 38; 1706-1711

52. Madan A, Borckardt JJ, Balliet WE, Barth KS, Delustro LM, Malcolm RM, Koch D, Willner I, Baliga P, Reuben A. Comprehensive psychosocial evaluation and management of liver

Adrian Reuben 2020

16

transplant candidates and recipients is associated with improved outcomes. Int J. Psychiatry 2015;49:279-295.

53. Madan S, Barth KS, Balliet WE, Hernandez-Tejada MD, Borckhardt JJ, Malcolm R, Willner I, Koch D, Reuben A. Chronic pain among liver transplant candidates. Prog Transplant 2012;22:379-384.

54. Fontana RJ, Ellerbe C, Durkalski VE, Rangnekar A, Reddy RK, Stravitz T, McGuire B, Davern T, Reuben A, Liou I, Fix O, Ganger DR, Chung RT, Schilsky M, Han S, Hynan LS, Sanders C, Lee WM; US Acute Liver Failure Study Group. Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicenter study. Liver Int. 2015;35:370-380.

55. Madan A, Borckardt JJ, Balliet WE, Barth KS, Delustro LM, Malcolm RM, Koch D, Willner I, Baliga P, Reuben A. Neurocognitive status is associated with all-cause mortality among psychiatric, high-risk liver transplant candidates and recipients. Int J Psychiatry Med. 2015;49:279-95

56. Stravitz RT, Reuben A, Mizrahi M, Lalazar G, Brown K, Gordon S, Ilan Y, Sanyal A. Use of the Methacetin Breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation. J. Hepatol 2015; 63: 1345-1351

57. Stravitz RT, Ellerbe C, Durkalski V, Reuben A, Lisman T, Lee WM and the Acute Liver Failure Study Group. Thrombocytopenia Is Associated with Multi-organ System Failure in Patients With Acute Liver Failure. Clinical Gastroenterology and Hepatology 2016; 14: 613-620

58. Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, Durkalski V, Larson AM, Liou I, Fix O, Schilsky M, McCashland T, Hay JE, Murray N, Shaikh OS, Ganger D, Zaman A, Han SB, Chung RT, Smith A, Brown R, Crippin J, Harrison ME, Koch D, Munoz S, Reddy KR, Rossaro L, Satyanarayana R, Hassanein T, Hanje AJ, Olson J, Subramanian R, Karvellas C, Hameed B, Sherker AH, Robuck P, Lee WM. Outcomes in adults with Acute Liver Failure between 1998 and 2013. An observational cohort study. Ann Intern Med. 2016 Ann Intern Med. 2016;164: 724-732

59. Bose S, Tholanikunnel TE, Reuben A, Tholanikunnel BG, Spicer EK. Regulation of nucleolin expression by miR-194, miR-206 and HuR. Molecular and Cellular Biochemistry 2016;417: 141-153

60. Koch DG, Tillman H, Durkalski V, Lee WM, Reuben A. Development of a Model to Predict Transplant-free Survival of Patients With Acute Liver Failure. Clin Gastroenterol Hepatol. 2016; 14: 1199-1206.

61. Roberts DW, Lee WM, Hinson JA, Bai S, Swearingen CJ, Stravitz RT, Reuben A, Letzig L, Simpson PM, Rule J, Fontana RJ, Ganger D, Reddy KR, Liou I, Fix O, James LP. An Immunoassay to Rapidly Measure Acetaminophen Protein Adducts Accurately Identifies Patients with Acute Liver Injury or Failure. Clin Gastroenterol Hepatol. 2016; 15: 555-562

62. Resnick E, Shteingart S, Melamud B, Bdolah-Abram T, Zalut T, Reuben A, Lurie Y. Enzyme pattern of biliary colic: A counterintuitive picture. World J Hepatol. 2016; 8:1629-1636

63. Stewart SH, Reuben A, Anton RF Relationship of Abnormal Chromatographic Pattern for Carbohydrate-Deficient Transferrin with Severe Liver Disease. Alcohol Alcohol. 2017; 52: 24-28

64. Fortune BE, Garcia-Tsao G, Ciarleglio M, Deng Y, Fallon MB, Sigal S, Chalasani NP, Lim JK, Reuben A, Vargas HE, Abrams G, Lewis MD, Hassanein T, Trotter JF, Sanyal AJ, Beavers KL, Ganger D, Thuluvath PJ, Grace ND, Groszmann RJ; Vapreotide Study Group.. Child-

Adrian Reuben 2020

17

Turcotte-Pugh Class is best at stratifying risk in variceal hemorrhage: Analysis of a U.S. multi-center prospective study. J Clin Gastroenterol. 2017; 51: 446-453

65. Koch DG, Speiser, JL, Durkalski V, Fontana RJ, Davern T, McGuire B, Stravitz RT, Larson AM, Liou I, Fix O, Schilsky M, McCashland T, Hay EJ, Murray N, Shaikh OS, Ganger D, Atif Zaman A, Steven B, Chung RT, Munoz S, Reddy KR, Rossaro L, Satyanarayana R, Hanje J, Olson J, Subramanian R, Karvellas C, Hameed B, Doo E, Sherker AH, Lee WM, Reuben A. The Natural History of Severe Acute Liver Injury Am J Gastroenterol 2017; 112:1389-139

66. Caldwell S, Intagliata N, The Coagulation in Liver Disease G, Gatt A, Reuben A, Farias A, et al. A summary of the 6th international conference on coagulation in liver disease: Discussion, debate, deliberations. Ann Hepatol. 2017;16:12-15.

67. Thomas A, Koch D, Marsteller W, Lewin D, Reuben A. An Analysis of the Clinical, Laboratory, and Histological Features of Striped, Punctate, and Nodular Gastric Antral Vascular Ectasia. Dig Dis Sci. 2018; 63: 966-973.

68. Stewart SH, Reuben A, Anton RF. Reply: Carbohydrate Deficient Transferrin Patients with Cirrhosis: A Tale of Bridges. Alcohol Alcohol 2018; 53: 351-352

69. Ganger DR, Rule J, Rakela J, Bass N, Reuben A, Stravitz RT, Sussman N, Larson AM, James L, Chiu C, Lee WM; Acute Liver Failure Study Group. Acute Liver Failure of Indeterminate Etiology: A Comprehensive Systematic Approach by An Expert Committee to Establish Causality Am J Gastroenterol. 2018; 113: 1319–1328

(b) Case Reports

1. Reuben A, Jourdan MH, Isaacs PET, McColl I. Spontaneous closure of choledochoduodenoscopy: Diagnosis by endoscopy and ERCP. Brit. J. Surgery 67:283-286, 1980.

2. Reuben A, Russel-Jones R, Lovel D. Bechet’s syndrome with colonic involvement and arterial thrombosis. Journal of the Royal Society of Medicine 73:520-524, 1980

3. Morse S, Reuben A, Strauss EB, Greenwood LH, Denny DF, August D, Flye WM. Liver transplantation rejection arteritis: Serial hepatic arteriography. Cardiovascular and Interventional Radiology 9:191-194, 1986

4. Perkal MF, Haber MM, Nelson K, Marks WH, Reuben A, West AB, Lorber MI. Cytomegalovirus appendicitis in a liver transplant recipient. Clin Transplantation 6:384-387, 1992.

5. Navarro V, Reuben A. Bleeding esophageal varices. N. Engl. J. Med. 331:1129, 1994. 6. Haber M, Reuben A, Burrell M, Oiverio P, Salem RR, West AB. Multifocal nodular

hyperplasia of the liver associated with hemihypertrophy and vascular malformations. Gastroenterology 108:1250-1262, 1995.

7. Madhotra R, Carter TD, Willner I, Reuben A. Reversible flaccid paraplegia after orthotopic liver transplantation. Am J. Gastroenterol. 96:1943-1944, 2000.

8. Baron LF, Reuben A. Radiological Case of the Month. Applied Radiology 9. Draganov P, Durrence H, Cox C, Reuben A. Alcohol-acetaminophen syndrome. Even

moderate social drinks are at risk. Postgraduate Medicine 107:189-195, 2000. 10. Avendano CE, Flume PA, Baliga P, Lewin DN, Strange C, Reuben A. Hepatopulmonary

syndrome occurring after orthotopic liver transplantation. Liver Transplant 7:1081-1084, 2001.

11. Evans J, Oates J, Shepherd M, Reuben A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J. Clin. Gastroenterol 42:862-863, 2008.

Adrian Reuben 2020

18

12. Koch DG, Caplan M, Reuben A. Pulmonary hypertension after liver transplantation: Case presentation and review of the literature. Liver Transpl. 15:407-412, 2009.

13. Theruvath TP, Izaar B, McGillicuddy JW, Stewart ES, Reuben A, Chavin KD. Hepatocellular adenoma in men: A rare cause of liver resection. Am. Surg. 77(3):373-376, 2011.

14. Marsteller WF, Lewin DN, Reuben A. The biopsy GAVE the diagnosis. Clin. Gastroenterol Hepatol 2012;10: e75-76.

(c) Book Chapters, Reviews, Editorials, Obituaries, Software and Symposia Proceedings

1. Reuben A, Howell KE, Boyer JL. Studies on the relationship between mixed lipid biliary micelles, pigment and protein in bile. In: Falk Symposium #29. Bile Acids and Lipids. Eds. Paumgartner G Stiehl A, Gerok W. 1981. MPT Press Ltd. England, pp. 153-156

2. Reuben A, Maton PN, Murphy GM, Dowling RH. Cholesterol synthesis and biliary cholesterol secretion in obesity. In: Falk Symposium #29. Bile Acids and Lipids. Eds. Paumgartner G Stiehl A, Gerok W. 1981. MPT Press Ltd. England, pp. 203-209.

3. Reuben A, Allen RM and Boyer JL. Intrahepatic sources of “biliary-like” bile acid-phospholipid-cholesterol micelles. In: Bile Acids and Cholesterol Health & Disease. Eds. Paumgartner G Stiehl A, Gerok W. 1983. MBT Press Ltd. England, pp. 61-66.

4. Reuben A. Bile Formation: Sites and Mechanisms. Hepatology 4:15S-24S, 1984. 5. Reuben A. Biliary proteins. Hepatology 4:46S-50S, 1984. 6. Reuben A. Physical State of Bilirubin and Organic Anions in Bile. Hepatology 4:212S-

214S, 1984. 7. Reuben A. (1986) Book Review on Cell surface science in medicine and pathology. By EN Wardle.

607 pp. New York: Elsevier Science Publishers, 1985. $60. Wiley Online Library. 8. Reuben A. (1987) Book Review. A colour atlas of gastrointestinal endoscopy. By KFR Schiller, R.

Cockel and RH Hunt. 240 pp. London, England: Chapman and Hall, 1986, 65£. Wiley Online Library; 1987.

9. Mittal RK, Reuben A, McCallum RW. Reply. Gastroenterology. 1987; 93: 1145. 10. Reuben A. Hepatitis C. Mediguide to Infectious Diseases 11:1-4,1991. 11. Shifman M, Reuben A, Bove J. Hepatitis Advisor. An Interactive Computer-Assisted

Program for the Interpretation of Hepatitis Serology. Center for Medical Informatics, Section of Digestive Diseases (Department of Internal Medicine) and Department of Laboratory Medicine, Yale University School of Medicine. 1992

12. Boyer JL and Reuben A. Chronic Hepatitis. Chapter 23. In: Diseases of the Liver, 6th Edition. Eds. Schiff I and Schiff ER. J. B Lippincott Co., Philadelphia. 1993

13. Reuben A. In Clinical Gastroenterology, 4th Edition. Ed. Spiro HM. McGraw-Hill Inc., New York. 1993 Chapter 40, General Considerations. Chapter 41, Congenital Disorders and other Pediatric Diseases of the Biliary Tract. Chapter 42, Gallstones and Their Consequences. Chapter 43, Inflammatory and Fibrotic Diseases of the Biliary Tree.

14. Moyer SM and Reuben A. Chapter 19, Procedures in Pediatric Hepatology. In Liver Disease in Children. Ed. Suchy FJ. Mosby. St Louis, 1994.

Adrian Reuben 2020

19

15. Reuben A. A 52-year old obese man with angina and melena. In Critical Care Pearls, 2nd Edition. Eds. Sahn SA and Heffner JE. Hanley and Belfus, Inc., Philadelphia, 1995

16. Levy MT, Trojanowska M, Reuben A. Amiloride: A Na+/H+ exchanger inhibitor, ameliorates collagen production by human stellate cells. Cells of the Hepatic Sinusoid, 1999; Vol. 7:198-200.

17. Reuben A. Long-term management of the liver transplant patient: Diabetes, Hyperlipidemia and Obesity. Liver Transplantation 2001; 7 (suppl. 1): S13-S21.

18. Madhotra R, Carter TD, Willner I, Reuben A. Surgery versus medical therapy for gastroesophageal reflux disease: Comment. Am J Gastroenterol. 2001;96: 1932-3.

19. Reuben A. Chapter 26. Methotrexate Controversies. In Drug-Induced Liver Disease. Eds. Kaplowitz N and DeLeve L. Marcel Decker, Inc., New York. 2002

20. Reuben A. Acute and Chronic Viral Hepatitis. In Conn’s Current Therapy, 54th Edition, 2002. Eds. Rakel and Bope. WB Saunders Company, pages 497-504.

21. Binder HJ and Reuben A. Chapter 44, Nutrient Digestion and Absorption. In Medical Physiology. Eds. Boron WF and Boulpaep EL. WB Saunders Company, Philadelphia. 2003

22. Reuben A and Groszmann RJ. Chapter 1. Portal Hypertension: A History. In Portal Hypertension: Pathobiology, Evaluation and Treatment. Eds. Sanyal A and Shah V. Humana Press, Inc., New Jersey, 2005.

23. Reuben A. Chapter 18: Jaundice, and Chapter 19: Spotting and Dealing with Physical Signs in chronic Liver Disease: A guided tour. In: The Modern Clinician’s Guide. Eds. Weinstein WM, Hawkey CJ, Bosch J. Elsevier Science. London UK, 2005.

24. Willner IR and Reuben A. Alcohol and the Liver. In: Current Opinion in Gastroenterology (Ed. R Moseley), 2005;21:323-330.

25. Binder HJ, Reuben A. Chapter 44: Nutrient Digestion and Absorption. Medical Physiology, 2nd Ed. Eds. Boron WF and Boulpaep EL. WB Saunders Company, Philadelphia, 2006.

26. Reuben A. Alcohol and the Liver. In: Current Opinion in Gastroenterology, 2006; 22: 263-271.

27. Reuben A. Alkol ve karaciğer. Curr Opin Gastroenterol. 2006;1(3):161-73. 28. Reuben A. Methotrexate Controversies. In: Drug-Induced Liver Disease 2nd Edition.

Eds. Kaplowitz N and DeLeve L. Informa Healthcare USA, Inc., New York, 2007. 29. Reuben A. Alcohol and the Liver. In: Current Opinion in Gastroenterology, 2007; 23:

283-291. 30. Reuben A. Needles in haystacks (editorial). Am. J. Gastroenterology 2007;102: 2444-

2446. 31. Reuben A. Alcohol and the Liver. In: Current Opinion in Gastroenterology, 2008; 24:

328-338. 32. Cirrhosis. CD-ROM 33. Reuben A. Renan Uflacker, MD March 16th 1949-June 12th 2011 Dedication 34. Reuben A. Hepatocellular carcinoma: Its past, present and future. Diagnosis and

Therapy of Hepatocellular Carcinoma. In: Clinics Liver Disease 2011; 15:xii-xvii. 35. Reuben A. Spotting and Dealing with Signs of Chronic Liver Disease: A Guided Tour. In:

Textbook of Clinical Gastroenterology and Hepatology, Second Edition. 2012 36. Reuben A. Jaundice. In: Textbook of Clinical Gastroenterology and Hepatology, Second

Edition. 2012

Adrian Reuben 2020

20

37. Reuben A. Hepatotoxicity of immunosuppressive drugs. In: Drug-Induced Liver Disease, 3rd Edition. Eds. Kaplowitz N and DeLeve L. Informa Healthcare USA, Inc., New York, 2013.

38. Reuben A. Caroline Armistead Riely, MD February 1st 1944–December 13th 2012. Hepatology. 2013; 57: 2550-2552.

39. Reuben A. Hepatocellular Carcinoma in Adults and Children. Preface. Clinics in Liver Disease, 2015;19(2): xiii-xvi.

40. Reuben A. Approach to the patient with abnormal liver tests and jaundice. Scientific American Gastroenterology, Hepatology and Endoscopy 2016

41. Reuben A. Examination of the abdomen. Clinical Liver Disease 2016; 7:143-150 42. Reuben, A. The Risk of Surgery in Patients with Liver Disease

1: Epidemiology, Pathophysiology, and Pre-operative Evaluation. In: Burakoff, R, editor. Scientific American Medicine [online]. Hamilton (ON): Decker Intellectual Properties; January 2018. DOI: 10.2310/7900.5481. 2. In: Burakoff, R, editor. Scientific American Medicine [online]. Hamilton (ON): Decker Intellectual Properties; January 2018. DOI: 10.2310/7900.5487.

43. Reuben A. Series Editor - Introduction to the online series A History of Hepatology 2020 (in press)

(d) Landmarks in Hepatology (A Series of Historical Essays in Hepatology)

1. Reuben A. Child Comes of Age. Hepatology 2002;35:244-245. 2. Reuben A. Ito Becomes a Star. Hepatology 2002;35:503-504. 3. Reuben A. Along Came a Spider. Hepatology 2002;35:735-736. 4. Reuben A. There is Nothin’ Like a Dame. Hepatology 2002;35:983-985. 5. Reuben A. By Indirections Find Directions Out. Hepatology 2002;35:1287-1289. 6. Reuben A. Where are the Gnomes of Yesteryear. Hepatology 2002;35:1554-1555. 7. Reuben A. Out Came Copious Water. Hepatology 2002;36:261-263. 8. Reuben A. Wine Hath Drowned More Men than the Sea. Hepatology 2002;36:516-518. 9. Reuben A. The Thin Red Line. Hepatology 2002;36:770-773. 10. Reuben A. An Eternal Golden Triangle. Hepatology 2002;36:1030-1033. 11. Reuben A. Leave Gourmandizing. Hepatology 2002;36:1303-1306. 12. Reuben A. Not Too Little, Not Too Much, but Just Right. Hepatology 2002;36:1555-58. 13. Reuben A. The serology of the Addison-Gull syndrome. Hepatology 2002;37:225-228. 14. Reuben A. Chopin’s serpin. Hepatology 2003;37:485-488. 15. Reuben A. Pearls of pathology. Hepatology 2003;37:715-718. 16. Reuben A. Sensei of Sendai. Hepatology 2003;37:952-955. 17. Reuben A. Absolute mitochondrion. Hepatology 2003;37:1228-1231. 18. Reuben A. The way to a man’s heart is through his liver. Hepatology 2003;37:1500-1502 19. Reuben A. The last gasp or Caveat Cenans. Hepatology 2003;38:273-276. 20. Reuben A. Now you see it, now you don’t. Hepatology 2003;38:781-784. 21. Reuben A. Illustrious, industrious and perhaps notorious. Hepatology 2003;38:1076-1069. 22. Reuben A. Just a second. Hepatology 2003;38:1316-1320. 23. Reuben A. A sheep in wolf’s clothing. Hepatology 2003;38:1596-1601.

Adrian Reuben 2020

21

24. Reuben A. Never say dye. Hepatology 2004;39:259-264. 25. Reuben A. Hy’s law. Hepatology 2004;39:574-578. 26. Reuben A. Old scratch. Hepatology 2004;39:870-874. 27. Reuben A. The liver has a body. Hepatology 2004;39:1179-1181. 28. Reuben A. Prometheus and Pandora: Together Again. Hepatology 2004;39:1460-1463. 29. Reuben A. Try, try, try again... and again. Hepatology 39;1750-1753 30. Reuben A. My cup runneth over. Hepatology 2004; 40: 503-507. 31. Reuben A. The legend of the lardaceous liver. Hepatology 2004; 40: 763-766. 32. Reuben A. A better mousetrap. Hepatology 2004; 40: 1023-1027. 33. Reuben A. Praise ye the god of iron. Hepatology 2004; 40: 1231-1234. 34. Reuben A. Au Conntraire, Professor Pasteur! Hepatology 2004; 40: 1478-1482. 35. Reuben A. The liver has a body – a Cook’s tour. Hepatology 2005; 41: 408-415. 36. Reuben A. The crab, the turkey and a malignant tale from the year of the rooster.

Hepatology 2005; 41:944-950. 37. Reuben A. A tree grows in the Liver, and now we can see it. Hepatology 2005; 41: 1201-

1206. 38. Reuben A. Prepared minds and the introduction of Imagnion for hepatic contagions.

Hepatology 2005; 41: 1437-1442. 39. Reuben A. The biliary cycle of Moritz Schiff. Hepatology 2005; 42: 500-505. 40. Reuben A. You’ve gotta have heart! Hepatology 2005; 42: 979-983. 41. Reuben A. First do no harm. Hepatology 2005 ;42: 1464-1470. 42. Reuben A. First do no harm. 2005. Hepatology. 2006;43(2 Suppl 1):S243-9. 43. Reuben A. True, true – but are they related? Hepatology 2006; 43: 635-639. 44. Reuben A. Seeing purple. Hepatology 2006; 43: 1403-1409. 45. Reuben A. Splendid isolation. Hepatology 2006; 44:

(e) Abstracts and presentations:

1. Reuben A, Narasimha K, Myers M, Wood T, Britton KE: An approach to the study of liver disorders using 123I BSP. Gut 15:837, 1974

2. Reuben A, Dilawari J, Cotton PB: Bleeding oesophagitis due to enforced recumbency. Gut 16:410, 1975.

3. Reuben A, Murphy GM, Dowling RH: Factors influencing the bioavailability of chenodeoxycoic acid (CDCA). Clin. Sci. Mol. Med. 54:15, 1978.

4. Reuben A, Dowling RH: Does obesity complicate chenodeoxycholic acid (CDCA) treatment of gallstones? Gut 19:A452, 1978.

5. Maton PN, Reuben A, Ellis HJ, Dowling RH. Does hepatic cholesterol synthesis influence biliary cholesterol, and bile acid secretion in man? Eur J Clin Invest. 1979 ;9:136.

6. Maton PN, Reuben A, Ellis HJ, Dowling RH: Hepatic cholesterol synthesis in cholelithiasis. Role of HMG COA reductase in determining biliary cholesterol secretion. Clin. Sci. Mol. Med. 56:13, 1979.

7. Reuben A, Maton PN, Quereshi Y, Dowling RH: Mechanism for biliary cholesterol supersaturation: biliary lipid secretion studies in obesity with and without gallstones. Clin. Sci. Mol. Med. 56: 1979.

8. Reuben A, Howell KE, Boyer JL: Bile salt-lipid micelles do not form complexes with pigment or proteins in bile under physiologic conditions. Gastroenterology 79:1048, 1980.

9. Reuben A, Allen RM, Boyer JL: Intrahepatic sources of “biliary-like” bile acid-phospholipid-cholesterol micelles. Gastroenterology 82:1241, 1982.

Adrian Reuben 2020

22

10. Reuben A, Allen RM, Ng OC, Boyer JL: Taurocholate reduces serum triglyceride production and hepatic Golgi lipoprotein content while stimulating biliary lipid secretion in the rat. Hepatology 3:871, 1983.

11. Mittal R, Reuben A, Magyar L, McCallum RW: Identification of bile acids in the esophagus during gastroesophageal reflux in man. Gastroenterology 86:1184, 1984.

12. Reuben A, Allen RM, Ng OC, Boyer JL. Total hepatic and Golgi triglycerides (TG) content is reduced during taurocholate (TC)-induced biliary lipid hypersecretion. Hepatology 4:777, 1984.

13. Zeniya M, Reuben A. Two secretory mechanisms for transfer of lipids into bile. Hepatology 4:1041, 1984.

14. Reuben A, Riely, CA, Lange R, Barwich KW, Flye MF. The value of hepatobiliary scanning in assessing graft function after liver transplantation. Hepatology 5:943, 1985.

15. Barwick KW, True LD, Reuben A, Riely CA, Flye MW. Histologic evaluation of rejection and other processes affecting liver allografts. Lab. Invest. 54:5a, 1985.

16. Zeniya M, Reuben A. Triton WR-1339-induced changes in serum lipids and biliary lipid secretion. Am J Physiol Endocrinol Metab. 1988; 254.

17. Katagiri K, Reuben A. Relationship between biliary secretion of newly synthesized and preformed cholesterol (CH). Hepatology 6:1168, 1986.

18. Reuben A, Dettman HD, Armitage IM. The use of 31p-Nuclear Magnetic Resonance Spectroscopy (31p-NMR) to detect lipid vesicles in bile. Hepatology 6:1169, 1986.

19. Reuben A, Allen RM. Taurocholate (TC)-induced phospholipid (PL) release from rat liver organelles. Hepatology 6: 11__, 1986.

20. Polio J, Better OS, Sterzel RB, Reuben A, Groszmann RJ. Renal hypertension and natriuresis in a rate model of portal hypertension: relationship to arterial bile acid levels. Hepatology 6: 1179, 1986.

21. Riely CA, Reuben A, Flye MW, Andiman A. Natural history of Epstein-Barr (EB) and other herpes virus infections after liver transplantation. A prospective longitudinal study. Hepatology 6: 1180, 1986.

22. Better OS, Polio J, Reuben A, Groszmann RJ, Sterzel B. Renal hypertension and impaired sodium conservation in rats with pre-hepatic portal hypertension. Kidney Int. 31:420, 1987.

23. Petrides, AS Luzi L, Reuben A, Riely CA, Defronza RA. Insulin-mediated glucose but not leucine metabolism is impaired in cirrhosis. Hepatology 7:1102, 1987.

24. Polio J, Better OS, Sterzel RB, Reuben A, Groszmann RJ. Portal hypertension reverses arterial hypertension in spontaneously hypertensive rats. Hepatology 7:1102, 1987.

25. Reuben A, Allen RM. Taurocholate transport by rat liver microsomes. Gastroenterology 94:A584, 1988.

26. Bonner GF, Reuben A. Use of nitro-benzo-oxa-diazo fluorescent phosphatidylcholine (NBD-PC) to study phospholipid transport in hepatocytes and bile. Hepatology 10:599, 1989.

27. Price MA, Burrell MI, Bennick M, Reuben A, Dobbins J. Biliary imaging and excretory dynamics after papillotomy in patients with an intact gallbladder. Radiology 173 (P); Supplement 87, 1989.

28. Reuben A, Allen RM. Taurocholate transport by rat liver Golgi vesicles. Gastroenterology 98: A624, 1990.

29. Evans J, Nathanson MH, Reuben A, Craft J. Intracellular distribution of PBC 95K during cell cycle. Arth. Rheum. 1991.

Adrian Reuben 2020

23

30. Chen M-C, Ananthanarayanan M, Reuben A. A 52K putative carrier protein for bile acid transport in rat liver microsomes. Hepatology 14:147A, 1991.

31. Allen RM, Reuben A. Bile acid transport in microsomes from bile duct-ligated rats. Hepatology 14:248A, 1991.

32. Mahl T, West AB, Kuo S, Riely CA, Reuben A. Methotrexate hepatotoxicity in psoriasis. Gastroenterology 102: A846, 1992.

33. Haber M, West AB, Reuben A. Lack of relationship between clinical, laboratory and histologic findings in chronic hepatitis C. Hepatology 16:203A, 1992.

34. Haber M, West AB, Reuben A. Relationship of alanine aminotransferase (ALT) to histologic findings in chronic hepatitis C. Gastroenterology 104: A912, 1993.

35. Petersen KF, Rothman DL, Reuben A, West AB, Shulman GI. Noninvasive determination of hepatic triglycerides hepatic triglyceride concentration in humans with 13C NMR spectroscopy. Hepatology 19: 311 (abst.) 1994.

36. Watanabe F, Reuben A. Ntcp is a candidate for the carrier that mediates bile acid transport in rat liver microscomes. Hepatology 22:320a, 1995.

37. Portwood G, Baliga P, Reuben A, Cunningham J. Utility of Endoscopic Retrograde Cholangiography (ERCP) and Percutaneous Transhepatic Cholangiography (PTC) following liver transplantation. Hepatology 24: , 1996.

38. Mishra G, Baliga P, Cofer JB, Reuben A. Clinical spectrum of Post-Transplant Lymphoproliferative Disorder (PTLD) in liver transplantation. Hepatology 24:548A, 1996.

39. Reuben A, Barritt J, Conrad A. Falsely low Hepatitis C Virus (HCV) RNA results. Hepatology 24: 386A, 1996.

40. Williams MC, Langston L, Baliga P, Soldevila-Pico C, Reuben A. Safety of steroid withdrawal in liver transplant recipients. Hepatology 24: 174A, 1996.

41. Bhaskar S, Cofer JB, Baliga P, Reuben A. Risk factors for recurrent hepatitis in patients after liver transplantation for hepatitis C. Hepatology 24: 298A, 1996.

42. Conrad A, Tong M, Reuben A, Bergendahl R, Keener K, Russell J, Barrett J, Schmidt P. Comparison of Plasma Preparation Tube (PPT™) and fresh frozen serum impact on stability of hepatitis C virus RNA by RT-PCR. Hepatology 24:386A, 1996.

43. Douzdjian V, Baliga P, Bhaskar R, Reuben A, Soldevila-Pico C, Rajagopalan PR. Univariate and multivariate analysis of risk factors for graft failure after liver transplants: A single-center experience. Hepatology 24:504A, 1996.

44. Douzdjian V, Baliga P, Bhaskar R, Reuben A, Soldevila-Pico C, Rajagopalan PR. Steroid-resistant acute rejection following liver transplantation: Risk factors and outcome. Hepatology 24:505A, 1996.

45. Schindler S, Uflacker R, Kay C, Reuben A. Reliability of Doppler ultrasound (US) for detecting dysfunction of transjugular intrahepatic portosystemic shunts (TIPS). Gastroenterology 112: 1997.

46. Verne N, Soldevila-Pico C, Spicer K, Reuben A. Autonomic dysfunction and gastroparesis in cirrhosis. Hepatology 26: 208A, 1997.

47. Foxworth T, Baliga P, Sindhi R, Reuben A. Reactivity to skin test antigens in liver transplant recipients. Hepatology 26: 508A, 1997.

48. Baillie GM, Baliga P, Douzdjian V, Reuben A, Stockdell R, Uber L, Sindhi R, Rajagopalan PR. Impact of treatment with Neoral versus Sandimmune on outcome variables in liver transplant recipients. Hepatology 26:237A, 1997.

49. Ustunsoz B, Uflacker R, Reuben A, Baliga P, Sindhi R. The human hepatic microcirculation in health and disease. Hepatology 26:275A, 1997.

Adrian Reuben 2020

24

50. Verne GN, Soldevila-Pico C, Spicer KM, Reuben A. Gastroparesis and autonomic dysfunction in cirrhosis. Gastroenterology 114: A855, 1998.

51. Sindhi R, Mundy D, Patil K, Taranto S, Baliga P, Reuben A, et al. Outcome Analysis Of Marginal Donor Liver Grafts Transplanted In Critically Ill Recipients-the Unos Registry Data 1991-1995. Transplantation. 1998; 65: 100.

52. Levy MT, Trojanowska M, Reuben A. Amiloride, an Na + /H+ exchanger inhibitor, inhibits collagen production by human hepatic stellate cells. Hepatology 28:299A, 1998.

53. Levy MT, Trojanowska M, Reuben A. Oncostatin M increases collagen production by cultured human hepatic stellate cells (HSCs). Hepatology 28: 439A, 1998.

54. Randall-Ray A, Reuben A, Brown K, Marsano L, Fontana R, Griffin L, Lok A. Effect of interferon (IFN) dose and pre-treatment HCV RNA level on the rate of viral clearance in patients with chronic hepatitis C (CHC). Hepatology 28: 477A, 1998.

55. Lok A, Reuben A, Marsano L, Brown K, Randall-Ray A, Morelli J, Gunaratnam N, Willner IR. High dose interferon significantly improves response in chronic hepatitis C patients with high viremia. Hepatology 28:701A, 1998.

56. Madhotra R, Willner IR, Reuben A. Esophagogastroduodenoscopy (egd) in the evaluation of asymptomatic liver transplant candidates-will esophagoscopy be sufficient? Gastrointest Endosc. 2000; 51 : AB83.

57. Madhotra R, Willner IW, Carter T, Reuben A. Reversible flaccid paraplegia following liver transplantation. Am J Gastroenterol. 2000; 95: 2588.

58. Rogers J, Mohammed H, Willner I, Reuben A, Lin A, Chavin KD, et al. Outcome Of Liver Transplantation For Autoimmune Hepatitis. American Journal of Transplantation Supplement. 2002; 2: 431.

59. Harvin G, Miles L, Huntley N Willner IR, Reuben A. The impact of Body Mass Index (BMI) on liver histology and treatment tolerability and efficacy in Chronic Hepatitis C (CHC). Gastroenterology 124: A717, 2003.

60. Znoyko IY, Trojanowska MN, Reuben A. Integrin signaling plays a role in the induction of Ets-1 gene expression in cultured human hepatic stellate cells (HSCs). Gastroenterology. 2003; 124: A717.

61. Znoyko I., Sohara N., Trojanowska M., and Reuben A. Induction of Ets1 expression in hepatic stellate cells (HSCs) by culture on MatrigelTM via integrin signaling. Gastroenterology 2003; 124: A704

62. Rogers J, Chavin K, Lin A, Lewin D, Reuben A, Willner I, et al. Preoperative Surveillance for Hepatocellular Carcinoma in Liver Transplant Candidates: Image Isn't Everything. Journal of Gastrointestinal Surgery. 2003; 7: 275.

63. Bhella, S, Doshi H, M. Reuben, A, et al. Diastolic dysfunction in end-stage liver disease post-liver transplant. J Cardiac Failure. 2004;10: S32.

64. Koch D, Willner I, Baliga P, Kenneth C, Angelo L, Reuben A. Post-transplant Lymphoproliferative Disorder (PTLD). Am J Gastroenterol. 2005; 100: S140.

65. Bunting TA, Potfay J, Koch D, et al. The association of patent foramen ovale with strokes and neurologic events during liver transplant and possible need for pre-operative closure. Am J Cardiol 2006; 98; 228M

66. Koch D, Malone M, Lewin DN et al. Bile duct proliferation (Bdp) is associated with intrapulmonary shunts (LPS) in patients with cirrhosis. Gastroenterology; 2007; 132: A201.

67. Koch D, Reuben A. Diabetes is an independent risk factor for ascites in patients with cirrhosis Hepatology 2008; 48: 1084A-1085A

68. Koch DG, Reuben A, Malone M. A New Look at the Pancytopenia Of Cirrhosis And The Effect On It Of Liver Transplantation (lt). Hepatology. 2009 ;50: 475A.

Adrian Reuben 2020

25

69. Koch DG, Reuben A. Increased Hepatic Venous (HV) Endothelin-1 (ET-1) is Associated With Intrapulmonary Vasodilatation (IPV) in Human Cirrhosis. Gastroenterology. 2010; 138: S-777

70. Shiffman ML, Lalazar G, Reuben A et al. Assessing Cirrhosis With A Non-invasive 13c Methacetin Breath Test: A Prospective Phase 3 Multicenter Trial. Hepatology 2010; 52: 1129A

71. Marsteller W, Reuben A, Lewin D. Biopsies of the Nodules GAVE Us the Diagnosis. Am J Gastroenterol. 2011; 106: S207 Townsend, J, Heard R, Steinberg DH, et al. Elevated international normalized ratio (inr) is not associated with increased bleeding in patients with end-stage liver disease undergoing invasive cardiac procedures. J Am Coll Cardiol 2011; 57; E1984

72. Greenberg CS, Wells JL, Vaughn CD, Reuben A. Platelet Count Plays a Major Role in Regulating Fibrin Formation in Cirrhosis: Clinical Study of Whole Blood Coagulation. Am Soc Hematology; 2011.

73. Fontana RJ, Ellerbe C, Durkalski V, et al. 2-year survival is significantly lower in Spontaneous survivors with non-acetaminophen Acute liver failure versus liver transplant recipients. Hepatology. 2012;56: 191A-2A.

74. Reuben A, Guggenheim GD, Hershkowitz AD,et al.. Hepatic 13C-methacetin Metabolism, Measured Using Exalenz Breathid©, Correlates Well with the Hepatic Venous Pressure Gradient (HVPG) in Patients with Cirrhosis. Hepatology. 2012; 56:759A.

75. Stravitz R, Mizrahi M, Lalazar G, Guggenheim GD, Hershkowitz AD, Oren IB, et al. The non-invasive 13c-methacetin Breath Test (MBT) predicts survival and complications of patients with cirrhosis: Interim analysis of a multicenter clinical trial. Hepatology. 2012; 56: 922A.

76. Balliet W, Madan A, Barth K et al. Common but undertreated chronic pain among individuals with end-stage liver disease considering liver transplantation. Ann Behav Med 2012; 43: S216

77. DeLustro LM, Madan A, Balliet WE, et al. Clinician rated judgment of historical compliance with medical recommendations is associated with pre-transplant hospitalizations among liver transplant candidates. Ann Behav Med 2013; 45: S309

78. Stravitz TR, Ellerbe C, Durkalski V, Reuben A, Lee WM. Thrombocytopenia in acute liver failure (ALF): a marker of multi-organ system failure and poor prognosis. Hepatology. 2013; 58: 262A.

79. Koch DG, Reuben A, Simpson KN. The Increasing Burden of Bacterial Infections in Hospitalized Patients with Cirrhosis: A 10-year Analysis of the National Inpatient Sample (NIS). Hepatology. 2013; 58: 1197A.

80. Fortune BE, Garcia-Tsao G, Ciarleglio M, et al. (2014). The Child-Turcotte-Pugh (CTP) is best at predicting 6-week mortality in patients with acute variceal hemorrhage (AVH): Analysis of a U.S. Multi-Center Prospective Study [Abstract 2061]. Hepatology, 60 (Supplement S1): 1202A.

81. Greenberg CS, Vaughn CD, Boylan A. Analyzing the Impact of Implementing a Systems-Based Hematologist into the Healthcare Delivery System at an Academic Medical Center. Am Soc Hematology 2015

82. Roberts DW, Hinson JA, Bai S, Lee WM, Stravitz TR, Reuben A, et al. A Rapid Test for Acetaminophen (APAP) Liver Injury. Hepatology. 2015; 62:1141A-1142A.

83. Greenberg CS, Vaughn CD, Meserve J, et al. Hematology Guided Correction of Coagulation Defects Using ROTEM Assays in Cirrhosis Can Reduce the Use of Fresh Frozen Plasma Prior to Invasive Procedures. Am Soc Hematology; 2016.

84. Ganger DR, Rule JA, Bass NM, Rakela J, Stravitz RT, Sussman NL, et al. Solving Indeterminate Etiology in Acute Liver Failure: The Contribution of Expert Opinion to the Process of Causality Adjudication. Hepatology; 2016; 63: 27A

(f) Multicenter trial participation

Adrian Reuben 2020

26

1. Parekh NK, Hynan LS, De Lemos J, Lee WM; Acute Liver Failure Study Group. Elevated

troponin I levels in acute liver failure: Is myocardial injury an integral part of acute liver failure? Hepatology 2007;45:1489-1498.

2. Leung PS, Rossaro L, Davis PA, Park O, Tanaka A, Kikuchi K, Miyakawa H, Norman GL, Lee W, Gershwin ME; Acute Liver Failure Study Group. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 2007;46:1436-1442.

3. Levitsky J, Duddempudi AT, Lakeman FD, Whitley RJ, Luby JP, Lee WM, Fontana RJ, Blei AT, Ison MG; US Acute Liver Failure Study Group. Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. Liver Transpl. 2008;14:1498.

4. Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH Jr, Fontana RJ, Lee WM; Pediatric and Adult Liver Failure Study Groups. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2008; 48:1167-1174.

5. Munoz SJ, Rajender Reddy K, Lee WM; Acute Liver Failure Study Group. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care 2008; 9:103-107.

6. Polson J, Wians FH Jr, Orsulak P, Fuller D, Murray NG, Koff JM, Khan AI, Balko JA, Hynan LS, Lee WM; Acute Liver Failure Study Group. False positive acetaminophen concentrations in patients with liver injury. 2008; 391: 24-30

7. Schiødt FV, Chung RT, Schilsky ML, N Engl J Med. 2009 Aug 6;361(6):580-93. 8. Acute Liver Failure Group. Outcome of acute liver failure in the elderly. Liver Transpl.

2009;15:1481-1487. 9. Coté GA, Gottstein JH, Daud A, Lee WM, Blei AT, Polson J, et al. The role of etiology in

the hyperamylasemia of acute liver failure. Am J Gastroenterol. 2009; 104: 592-7. 10. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TJ 2nd,

Murray NG, McCashland T, Reisch JS, Robuck PR; Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009; 137: 856-64

11. Coté GA, Gottstein JH, Daud A, Blei AT; Acute Liver Failure Study Group. The role of etiology in the hyperamylasemia of acute liver failure. Am. J. Gastroenterol 2009; 104:592-597.

12. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361: 580-93.

13. Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG; IDEAL Study Team. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010; 139:1602-11.

14. Ajmera V, Xia G, Vaughan G, Forbi JC, Ganova-Raeva LM, Khudyakov Y, Opio CK, Taylor R, Restrepo R, Munoz S, Fontana RJ, Lee WM; Acute Liver Failure Study Group. What factors determine the severity of hepatitis A-related acute liver failure? J Viral Hepat. 2011;18: e167-74.

15. Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexton AS, Teuber P. Terlipressin Study Group: Impact of liver transplantation

Adrian Reuben 2020

27

on the survival of patients treated for hepatorenal syndrome type I. Liver Transplantation 2011; 17:1328-1332.

16. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2011; 55: 315-321

17. Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchinson JG, Sulkowski MS. IDEAL study team. Racial differences in hepatitis C treatment eligibility. Hepatology 2011;54:70-78.

18. Stravitz RT, Lefkowitch JH, Fontana RJ, Gershwin ME, Leung PS, Sterling RK, Manns MP, Norman GL, Lee WM; Acute Liver Failure Study Group. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011;53:517-526.

19. Poordad F, McCone J Jr, Bacon BR, et al and SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364:1195-1206.

20. Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appendrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P. Terlipressin Study Group. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011; 17: 1328.

21. Stravitz RT, Lefkowitch JH, Fontana RJ, Gershwin ME, Leung PS, Sterling RK, Manns MP, Norman GL, Lee WM; Acute Liver Failure Study Group. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011; 53: 517-26.

22. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J. Hepatol 2011;55:315-321.

23. Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; IDEAL Study Team. Racial differences in hepatitis C treatment eligibility. Hepatology 2011; 54: 70-78

24. Dao DY, Serembra E, Ajmera V, Sanders C, Hynan LS, Lee WM, Acute Liver Failure Group. Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig. Dis. Sc. 2012;57:1349-1357.

25. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR, SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012;143:608-618.

26. Dao DY, Hynan LS, Yuan HJ, Sanders C, Balko J, Attar N, Lok AS, Word RA, Lee Wm, Acute Liver Failure Group. Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology 2012;55:676-684.

27. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard t, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR, SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012;143:608-618.

Adrian Reuben 2020

28

28. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass Ca, Jacobson IM, SPRINT-2 Trial Investigators. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 2013; 57: 974-984.

29. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS, Protocol 6086 Investigators. Effects of ribavirin dose reduction vs. erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection – a randomized trial. Gastroenterology 2013; 145:1035-1044.

30. Metushi IG, Sanders C, Acute Liver Failure Study Group, Lee WM, Uetrecht J. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid induced liver failure. Hepatology 2014;59:1084-1093.

31. Karkhanis J, Verna EC, Chang MS, Stravits RT, Schlinsky M, Lee WM, Brown RS Jr, Acute Liver Failure Study Group. Steroid use in acute liver failure. Hepatology 2014; 59 :612-621.

32. Court MH, Peter I, Hazarika S, Vasiadi M, Greenblatt DJ, Lee WM; Acute Liver Failure Study Group. Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab Dispos. 2014;42:28-32.

33. Dubin PH, Yuan H, Devine RK, Hynan LS, Jain MK, Lee WM, Acute Liver Failure Study Group. Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. J. Med. Virol. 2014;86:1507-1514.

34. Long D, Fix OK, Deng X, Seielstad M, Lauring AS; Acute Liver Failure Study Group. Whole genome sequencing to identify host genetic risk factors for severe outcomes of hepatitis A virus infection. J. Med. Virol. 2014;86:1661-1668.

35. Karvellas CJ, Fix OK, Battenhouse H, Durkalski V, Sanders C, Lee WM; U S Acute Liver Failure Study Group. US Acute Liver Failure Study Group. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit. Care Med. 2014; 42: 1157-1167.

36. Karvellas CJ, Cavazos J, Battenhouse H, Durkalski V, Balko J, Sanders C, Lee WM; US Acute Liver Failure Study Group. Karvellas CJ, Cavazos J, Battenhouse H, Durkalski V, Balko J, Sanders C, Lee WM; US Acute Liver Failure Study Group. Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure: a retrospective cohort study. Clin Gastroenterol Hepatol. 2014;12:1942-9.

37. Long D, Fix OK, Deng X, Seielstad M, Lauring AS; Acute Liver Failure Study Group. Whole genome sequencing to identify host genetic risk factors for severe outcomes of hepatitis a virus infection. J Med Virol. 2014; 86: 1661-8

38. Dubin PH, Yuan H, Devine RK, Hynan LS, Jain MK, Lee WM; Acute Liver Failure Study Group. Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. J Med Virol. 2014; 86:1507-14.

39. Long D, Fix OK, Deng X, Seielstad M, Lauring AS; Acute Liver Failure Study Group. Whole genome sequencing to identify host genetic risk factors for severe outcomes of hepatitis a virus infection. J Med Virol. 2014; 86:1661-8.

40. Karvellas CJ, Cavazos J, Battenhouse H, Durkalski V, Balko J, Sanders C, Lee WM; US Acute Liver Failure Study Group. Effects of antimicrobial prophylaxis and blood stream

Adrian Reuben 2020

29

infections in patients with acute liver failure: a retrospective cohort study. Clin Gastroenterol Hepatol. 2014; 12: 1942-9.

41. Karvellas CJ, Fix OK, Battenhouse H, Durkalski V, Sanders C, Lee WM; U S Acute Liver Failure Study Group. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit Care Med. 2014;42: 1157-67

42. Rule JA, Hynan LS, Attar N, Sanders C, Korzun WJ, Lee WM, et al. Procalcitonin identifies cell injury, not bacterial infection, in acute liver failure. PLoS ONE. 2015; 10

43. Srungaram P, Rule JA, Yuan HJ, Reimold A, Dahl B, Sanders C, Lee WM; Acute Liver Failure Study Group. Plasma osteopontin in acute liver failure. Cytokine 2015;73:270-276.

44. Speiser JL, Lee WM, Karvellas CJ. Predicting outcome on admission and post-admission for acetaminophen-induced acute liver failure using classification and regression tree models. PLoS ONE. 2015; 10: e0122929.

45. Laursen TL, Sandahl TD, Støy S, Schiødt F, Lee WM, Vilstrup H, Thiel S, Grønbaek H; US Acute Liver Failure Study Group. Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure. Liver Int. 2015; 35: 756-763.

46. Srungaram P, Rule JA, Yuan JH, Reimold A, Dahl B, Sanders C, Lee WM, The Acute Liver Failure Study Group. Plasma osteopontin in acute liver failure. Cytokine 2015; 73: 270-276.

47. Speiser JL, Lee WM, Karvellas CJ; US Acute Liver Failure Study Group. Predicting failure using classification and regression tree models. Stat Med. 2014; 34: 887-99

48. Speiser JL, Lee WM, Karvellas CJ; US Acute Liver Failure Study Group. Predicting outcome on admission and post-admission for acetaminophen-induced acute liver failure using classification and regression tree models. PLoS One. 2015; 10: e0122929.

49. Basta G, Del Turco S, Navarra T, et al. Acute Liver Failure Study Group. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure. Liver Transpl. 2015; 21: 847-54

50. Kaur, G.Leslie, E. M.Tillman, H. et al. Detection of Ophthalmic Acid in Serum from Acetaminophen-Induced Acute Liver Failure Patients Is More Frequent in Non-Survivors. PLoS One 2015; 10: e0139299

51. Karvellas, C. J.Tillman, H.Leung, A., et al. Acute liver injury and acute liver failure from mushroom poisoning in North America. Liver Int. 2016; 36; 1043-1050

52. Rosen, H. R.Biggins, S. W. Niki, T, et al. Association Between Plasma Level of Galectin-9 and Survival of Patients With Drug-Induced Acute Liver Failure. Clin Gastroenterol Hepatol. 2016; 14: 606-612

53. Randesi M, Levran O, Correa da Rosa J, Hankins J, Rule J, Kreek MJ, Lee WM; Acute Liver Failure Study Group. Association of Variants of Arginine Vasopressin and Arginine Vasopressin Receptor 1A With Severe Acetaminophen Liver Injury. Cell Mol Gastroenterol Hepatol. 2017; 3: 500-505

54. Karvellas CJ, Cardoso FS, Gottfried M, Reddy KR, Hanje AJ, Ganger D, et al. HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death. Clin Gastroenterol Hepatol. 2017;15 :113-22.

SUBMITTED FOR PUBLICATION: (g)

Adrian Reuben 2020

30

IN PREPARATION: (h).

Reuben A, Ilan Y. Hepatic 13C-Methacetin metabolism correlates well with the hepatic venous pressure gradient (HVPG) in patients with cirrhosis – Results of a pilot study

Reuben A. Myths of the INR: A review of the use of fresh frozen plasma in patients with liver disease.

Ashkenazi I, Reuben A, Lurie Y. Characterization of the laboratory and clinical findings of patients diagnosed with drug-induced liver injury as a tool to aid diagnosis Revised February 19th, 2020